Bcr-Abl

Catalog No.Inhibitor Name Bcr-AblAblOther
A10290Dasatinib
****
****
Src,c-Kit (D816V),c-Kit (wt)
A10468Imatinib Mesylate
*
c-Kit,PDGFR
A10108Saracatinib
**
c-Src,LCK,EGFR (L861Q)
A10080Ponatinib
****
****
PDGFRα,VEGFR2,FGFR1
A10644Nilotinib
**
A10715Danusertib
**
**
Aurora A,TrkA,RET
A10095AT9283
***
JAK3,JAK2,Aurora B
A10988Degrasyn
*
DUB
A10119Bafetinib
***
***
Lyn
A10508KW-2449
**
***
FLT3 (D835Y),FLT3,FGFR1
A10661NVP-BHG712
*
EphB4,C-Raf,c-Src
A11200Rebastinib
***
FLT3,KDR,Tie-2
A15849GZD824 Dimesylate
****
****
A11439GNF-2
*
A15887GNF-7
***
*
A13029Radotinib
**
A16320Dasatinib Monohydrate
****
****
Src,c-Kit (D816V),c-Kit (wt)
A13237GNF-5
*
A13120PD173955
***
Src
A11379DPH
A13530Flumatinib mesylate
****
PDGFRβ, c-Kit

Notes:
1.Hover mouse over " * " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " * " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

43 Item(s)

per page

Set Descending Direction
  1. CHMFL-ABL-039

    Catalog No. A13182
    Quick View
    BCR-ABL inhibitor
    CHMFL-ABL-039 is a type II native ABL kinase and drug-resistant V299L mutant BCR-ABL inhibitor with the IC50s of 7.9 nM and 27.9 nM, respectively. CHMFL-ABL-039 is used in the research of chronic myeloid leukemia. Learn More
  2. GNF-7

    Catalog No. A15887
    Quick View
    Bcr-Abl inhibitor
    GNF-7 is a potent type-II kinase Bcr-Abl inhibitor with IC50 of <5 nM, 61 nM, 122 nM, 136 nM, and 133 nM for M351T, T315I, E255 V, G250E, and c-Abl, respectively. Learn More
  3. GZD824 Dimesylate

    Catalog No. A15849
    Quick View
    Bcr-Abl Inhibitor
    GZD824 is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively. Learn More
  4. DPH

    Catalog No. A11379
    Quick View
    c-ABL activitor
    DPH is a c-ABL activitor. Learn More
  5. Lyn-IN-1

    Catalog No. A16265
    Quick View
    dual Bcr-Abl/Lyn inhibitor
    Lyn-IN-1 is a potent and selective dual Bcr-Abl/Lyn inhibitor, extracted from patent WO2014169128A1. Learn More
  6. ON 146040

    Catalog No. A16266
    Quick View
    dual PI3K and BCR-ABL inhibitor
    ON 146040 is the first dual PI3K and BCR-ABL inhibitor that targets the STAT3 and STAT5 pathways; inhibits PI3K α/δ isoforms with IC50 of 14/20 nM. Learn More
  7. Dasatinib Monohydrate

    Catalog No. A16320
    Quick View
    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively. Learn More
  8. SNIPER(ABL)-062

    Catalog No. A18567
    Quick View
    ABL inhibitor
    SNIPER(ABL)-062, in which an ABL inhibitor is linked to a ligand of cIAP1 via a linker containing a variable polyethylene glycol (PEG) unit, shows a potent activity to degrade the BCR-ABL protein. Learn More
  9. CZC-8004

    Catalog No. A19444
    Quick View
    ABL inhibitor
    CZC-8004 is a pan-kinase inhibitor and binds a range of tyrosine kinases, including ABL kinase. Learn More
  10. CHMFL-ABL-121

    Catalog No. A19079
    Quick View
    ABL2 inhibitor
    CHMFL-ABL-121 is a highly potent type II ABL kinase inhibitor with IC50s of 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein, respectively. Learn More
  11. Saracatinib (AZD0530)

    Catalog No. A10108
    Quick View
    Src/Abl inhibitor
    Saracatinib (AZD0530) is a highly selective, orally available, dual-specific Src/Abl kinase inhibitor with IC50 of 2.7 and 30 nM for c-Src and Abl kinase, respectively. Learn More
  12. BCR-ABL-IN-1

    Catalog No. A12496
    Quick View
    BCR-ABL inhibitor
    BCR-ABL-IN-1 is an inhibitor of BCR-ABL tyrosine kinase, with a pIC50 of 6.46, and may be used in the research of chronic myelogenous leukemia. Learn More
  13. CHMFL-ABL/KIT-155

    Catalog No. A12421
    Quick View
    ABL/c-KIT dual kinase inhibitor
    CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor. Learn More
  14. 1-Naphthyl PP1 hydrochloride

    Catalog No. A21790
    Quick View
    Src/c-Abl inhibitor
    1-Naphthyl PP1 hydrochloride is a selective inhibitor of src family kinases v-Src and c-Fyn as well as the tyrosine kinase c-Abl (IC50 values are 1.0, 0.6, 0.6, 18 and 22 μM for v-Src, c-Fyn, c-Abl, CDK2 and CAMK II respectively). Learn More
  15. BCR-ABL-IN-2

    Catalog No. A21043
    Quick View
    BCR-ABL inhibitor
    BCR-ABL-IN-2 is an inhibitor of BCR-ABL1 tyrosine kinase, with IC50s of 57 nM, 773 nm for ABL1native and ABL1T315I, respectively. Learn More
  16. AZD0424

    Catalog No. A19488
    Quick View
    Src/Abl kinase inhibitor
    AZD0424 is an orally active, and dual selective Src/Abl kinase inhibitor with potential antineoplastic activity. AZD0424 induces apoptosis and cell cycle arrest in lymphoma cells. Learn More
  17. Asciminib

    Catalog No. A19658
    Quick View
    Bcr-Abl inhibitor
    Asciminib (ABL001) is a potent and selective allosteric Bcr-Abl inhibitor; inhibits Ba/F3 cells grown with an IC50 of 0.25 nM. Learn More
  18. CT-721

    Catalog No. A19742
    Quick View
    Bcr-Abl kinase inhibitor
    CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor with an IC50 of 21.3 nM for wild-type Bcr-Abl kinase, and possesses anti-chronic myeloid leukemia (CML) activities. Learn More
  19. GMB475

    Catalog No. A22279
    Quick View
    BCR-ABL1 tyrosine kinase degrader
    GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. Learn More
  20. Imatinib (Gleevec)

    Catalog No. A10259
    Quick View
    PDGFR inhibitor
    Imatinib (Gleevec) is a number of tyrosine kinase enzymes specific inhibitor. Learn More
  21. AT9283

    Catalog No. A10095
    Quick View
    Aurora/JAK inhibitor
    AT9283 inhibits aurora kinase A and B and targets other tyrosine and serine/threonine kinases associated with myeloid cell proliferation. Learn More
  22. AP24534 (Ponatinib)

    Catalog No. A10080
    Quick View
    BCR-ABL inhibitor
    AP24534 (Ponatinib) is a potent multi-kinase and pan-BCR-ABL inhibitor. Learn More
  23. Flumatinib mesylate

    Catalog No. A13530
    Quick View
    c-Abl/c-Kit/PDGRFβ inhibitor
    Flumatinib mesylate can reduce the expression of C-MYC, HIF-1 a and VEGF in U266 cell line in a time- and dose-dependent manners, so flumatinib mesylate may become a new drug for MM therapy. Learn More
  24. Danusertib (PHA-739358)

    Catalog No. A10715
    Quick View
    Aurora inhibitor
    Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2 Learn More
  25. Bafetinib (INNO-406)

    Catalog No. A10119
    Quick View
    Bcr-Abl inhibitor
    Bafetinib ((INNO-406) is a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia. Learn More
  26. Dasatinib (BMS-354825)

    Catalog No. A10290
    Quick View
    Abl-Src inhibitor
    Dasatinib (BMS-354825) is an oral multi- BCR/ABL and Src family tyrosine kinase inhibitor. The main targets of dasatinib, are BCR/ABL, Src, c-Kit, ephrin receptors, and several other tyrosine kinases, but not erbB kinases such as EGFR or Her2. Learn More
  27. Imatinib Mesylate

    Catalog No. A10468
    Quick View
    Bcr-Abl inhibitor
    Imatinib mesylate, a selective tyrosine kinase inhibitor, induced a sustained objective response in treating gastrointestinal stromal tumors with the inhibition of the KIT signal-transduction pathway. Learn More
  28. Nilotinib (AMN-107)

    Catalog No. A10644
    Quick View
    Bcr-Abl inhibitor
    Nilotinib is a Bcr-Abl inhibitor with IC50 less than 30 nM. Learn More
  29. NVP-BHG712

    Catalog No. A10661
    Quick View
    EphB4 inhibitor
    NVP-BHG712 is a selective inhibitor of EphB4 kinase that exhibits selectivity for EphB4 over more than 40 other kinases in vitro, including FGFR3. Learn More
  30. DCC-2036 (Rebastinib)

    Catalog No. A11200
    Quick View
    Bcr-Abl inhibitor

    DCC-2036 is an orally bioavailable small-molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity.

    Learn More
  31. PP121

    Catalog No. A11207
    Quick View
    PI3K Inhibitor
    PP121 is a dual inhibitor of receptor tyrosine kinases (RTKs) (IC50 < 0.02 μM for Abl, Src, VEGFR-2 and PDGFR) and PI 3-K family kinases (IC50 < 0.06 μM for p110α, DNA-PK and mTOR). Learn More
  32. WP1130 (Degrasyn)

    Catalog No. A10988
    Quick View
    DUB/Bcr/ABL Inhibitor
    WP1130 (Degrasyn) is a novel selective small molecular deubiquitinase inhibitor and a Bcr/Abl destruction pathway activator that specifically and rapidly down-regulates both wild-type and mutant Bcr/Abl protein without affecting bcr/abl gene expression in chronic myelogenous leukemia (CML) cells. Learn More
  33. KW-2449

    Catalog No. A10508
    Quick View
    FLT3/FGFR/Bcr-Abl/Aurora Inhibitor
    KW-2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase. Learn More
  34. NRC-AN-019

    Catalog No. A13562
    Quick View
    Bcr-Abl inhibitor
    NRC-AN-019 is an orally administered tyrosine kinase inhibitor (TKI) of the Bcr-Abl protein-tyrosine kinase. NRC-AN-019 is more effective in inhibiting angiogenic potential and proliferation of both MDAMB231 and HTB20/BT474 cells. Learn More
  35. GNF 2

    Catalog No. A11439
    Quick View
    Bcr-Abl inhibitor
    GNF 2 is a Bcr-abl inhibitor that inhibits proliferation and induces apoptosis in Bcr-abl-expressing cells. Learn More
  36. XL-228

    Catalog No. A13069
    Quick View
    IGF-1R, Aurora, FGFR, ABL, SRC inhibitor
    XL228 is a protein kinase inhibitor targeting IGF1R, the AURORA kinases, FGFR1-3, ABL and SRC family kinases. XL228 is an Aurora A inhibitor (IC50, f3 nmol/L) that has shown potent biochemical activity against ABL1 (Ki, 5 nmol/L), as well as the BCR-ABL1 T315I (Ki, 1.4 nmol/L) kinases. Learn More
  37. GZD824

    Catalog No. A16264
    Quick View
    Bcr-Abl inhibitor
    GZD824 is a novel orally bioavailable inhibitor against a broad spectrum of Bcr-Abl mutants including T315I. Learn More
  38. Flumatinib

    Catalog No. A16258
    Quick View
    multi-kinase inhibitor
    Flumatinib is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRbeta and c-Kit respectively. Learn More
  39. PD173955

    Catalog No. A13120
    Quick View
    Bcr-Abl inhibitor
    PD-173955 is a src tyrosine kinase inhibitor. PD173955 inhibited Bcr-Abl-dependent cell growth. PD173955 showed cell cycle arrest in G(1). PD173955 has an IC(50) of 1-2 nM in kinase inhibition assays of Bcr-Abl, and in cellular growth assays it inhibits Bcr-Abl-dependent substrate tyrosine phosphorylation. PD173955 inhibited kit ligand-dependent c-kit autophosphorylation (IC(50) = approximately 25 nM) and kit ligand-dependent proliferation of M07e cells (IC(50) = 40 nM) but had a lesser effect on interleukin 3-dependent (IC(50) = 250 nM) or granulocyte macrophage colony-stimulating factor (IC(50) = 1 microM)-dependent cell growth. Learn More
  40. GNF-5

    Catalog No. A13237
    Quick View
    Bcr-Abl inhibitor
    GNF-5 is a selective allosteric inhibitor of BCR-ABL. Learn More
  41. Radotinib (IY-5511)

    Catalog No. A13029
    Quick View
    Bcr-Abl tyrosine inhibitor‎
    Radotinib is a novel and selective Bcl-Abl tyrosine kinase inhibitor Learn More
  42. AST 487

    Catalog No. A15003
    Quick View
    RET kinase inhibitor
    AST487 is a Ret kinase inhibitor/FLT3 inhibitor with IC50 of 0.88 uM for Ret. Learn More
  43. Nilotinib monohydrochloride monohydrate

    Catalog No. A15186
    Quick View
    Bcr-Abl inhibitor
    Nilotinib is a Bcr-Abl inhibitor with IC50 less than 30 nM. Learn More

43 Item(s)

per page

Set Descending Direction
Rewards